Amphista Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
65
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$16.9M
- Investors
-
9
Amphista Therapeutics General Information
Description
Developer of next-generation targeted protein degradation therapeutics designed to treat a range of diseases. The company's therapeutics advance novel approaches in targeted protein degradation to create a new generation of therapies with improved efficacy and identify the cell's degradation machinery to modulate the abundance of proteins that are responsible for disease progression, enabling healthcare providers to improve the lives of patients.
Contact Information
Website
www.amphista.comCorporate Office
- The Cori Building
- Granta Park, Great Abington
- Cambridge CB21 6GQ
- England, United Kingdom
Corporate Office
- The Cori Building
- Granta Park, Great Abington
- Cambridge CB21 6GQ
- England, United Kingdom
Amphista Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 24-Oct-2025 | $16.9M | Completed | Pre-Clinical Trials | ||
| 5. Early Stage VC (Series B) | 17-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 07-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | Completed | Startup | ||||
| 2. Accelerator/Incubator | 01-Jan-2020 | $65.6K | $65.6K | Completed | Startup | |
| 1. University Spin-Out | 20-Dec-2017 | Completed | Startup |
Amphista Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series A | 913,332 | $0.000134 | $1.21 | $1.21 | 1x | $1.21 | 3.69% | |
| Series A | 5,829,062 | $0.000134 | $1.34 | $1.34 | 1x | $1.34 | 23.57% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Amphista Therapeutics Comparisons
Industry
Financing
Details
Amphista Therapeutics Competitors (4)
One of Amphista Therapeutics’s 4 competitors is Catamaran Bio, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Catamaran Bio | Venture Capital-Backed | Boston, MA | ||||
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Cullgen | Formerly VC-backed | San Diego, CA | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA |
Amphista Therapeutics Patents
Amphista Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202509684-D0 | Compounds for first line therapy | Pending | 18-Jun-2025 | ||
| GB-202509687-D0 | Compounds for targeted protein degradation | Pending | 18-Jun-2025 | ||
| GB-202509688-D0 | Compounds for targeted protein degradation | Pending | 18-Jun-2025 | ||
| GB-202509690-D0 | Compounds for treating resistant patients | Pending | 18-Jun-2025 | ||
| GB-202509686-D0 | Pharmaceutical combinations | Pending | 18-Jun-2025 |
Amphista Therapeutics Signals
Amphista Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Gilde Healthcare | PE/Buyout | Minority | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | ||
| SV Health Investors | PE/Buyout | Minority |
Amphista Therapeutics FAQs
-
When was Amphista Therapeutics founded?
Amphista Therapeutics was founded in 2017.
-
Where is Amphista Therapeutics headquartered?
Amphista Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Amphista Therapeutics?
Amphista Therapeutics has 65 total employees.
-
What industry is Amphista Therapeutics in?
Amphista Therapeutics’s primary industry is Drug Discovery.
-
Is Amphista Therapeutics a private or public company?
Amphista Therapeutics is a Private company.
-
What is the current valuation of Amphista Therapeutics?
The current valuation of Amphista Therapeutics is .
-
What is Amphista Therapeutics’s current revenue?
The current revenue for Amphista Therapeutics is .
-
How much funding has Amphista Therapeutics raised over time?
Amphista Therapeutics has raised $78.5M.
-
Who are Amphista Therapeutics’s investors?
Eli Lilly and Company Foundation, Forbion, Gilde Healthcare, Novartis Venture Fund, and SV Health Investors are 5 of 9 investors who have invested in Amphista Therapeutics.
-
Who are Amphista Therapeutics’s competitors?
Catamaran Bio, Kymera Therapeutics, Cullgen, and Nurix Therapeutics are competitors of Amphista Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process